


1




2



3




4




5



6



7



8




9



10

Medical Cannabis Safety




In accordance with other studies evaluating the safety of cannabis treatment over all indications, **cannabis was found to be safe and well tolerated.**

Thirty percent of patients reported at least one side effect at six months, but the side effects were **relatively minor: dizziness, dry mouth, increased appetite, sleepiness and psychoactive effect.**

Lihi Bar-Lev Schleider, Raphael Mechoulam, Violeta Lederman, Mario Hilou, Ori Lencovsky, Oded Betzalel, Liat Shibo, Victor Novack. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine. 2018;49:37-43.


11



Although robust, the main problem with anti-cancer research today is that it is still limited to cell lines and animal studies, precluding meaningful conclusions and extrapolations in human cancer

Turkmen I, Bar-Sela G. Cannabis for cancer – Illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. 2019 Mar;28(3):265-290. doi: 10.1080/13543784.2019.1561859. Epub 2018 Dec 25. PMID: 30572744.

12




13

**Table 1. Anti-cancer effects of cannabinoids in various cancer cell lines**

Cancer Type	Model/Cell Line	Compound	Effective Dose	Effects	References
Breast	MCF-7	Cannabidiol (CBD)	8.2 $\mu$ M/2.6 mg/L		
		CBD-rich extract (~70% CBD)	6.0 $\mu$ M/2.7 mg/L		[13]
		$\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC)	14.2 $\mu$ M/4.5 mg/L	Inhibition of cancer cell growth and proliferation	
	MDA-MB-23	AEA	1.4 $\mu$ M/0.5 mg/L		[53]
		CBD	2.2 $\mu$ M/0.7 mg/L	Inhibition of cancer cell growth, induction of apoptosis	[54]
		WIN-55,212-2, JWH-133	10 $\mu$ M/3 mg/L, 10 $\mu$ M/3.1 mg/L	Inhibition of proliferation	[55]
	Xenograph-MDA-MD-231 cells	CBD	5 mg/kg (i.p.)		
		CBD-rich extract (~70% CBD)	6.5 mg/kg (i.p.)	Reduced tumour size and volume	[13]
Cervical	SiHa		3.2 $\mu$ g/mL/3.2 mg/L		
		Hi-La	3.2 $\mu$ g/mL/3.2 mg/L		
		CBD	1.5 $\mu$ g/mL/1.5 mg/L	Inhibition of cancer cell growth, induction of apoptosis	[46]
	HCT-15				
Colon	HCT-8				
	SW-620				
	HCA-7	CB-13	>50 nmol/L/0.02 mg/L	Inhibition of cancer cell growth	[49]
	HCT-15				
	HCT-116	CBG	$\geq 0.1$ $\mu$ M/0.9 mg/L	Reduced viability of cancer cells	
	Xenograph-HCT-116	CBG	3 and 10 mg/kg (i.p.)	Inhibition of tumour growth	[56]

14



15

### Ongoing Clinical Trials

- THC, CBD combinations
- THC, CBD independent or combined with chemotherapies
- THC, CBD independent or combined with radiotherapies
- THC, CBD independent or combined with immunotherapies

16



17

18

19

20

*Caution....*

In a multi-variant model, the authors found significantly reduced response rate to immunotherapy in a cohort of 140 patients with, and without cannabinoid treatment, after taking into account confounders such as performance status and Cannabis composition.

Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. 2019 Mar;28(3):285-296. doi: 10.1080/13543784.2019.1561859. Epub 2018 Dec 29. PMID: 30572744.

21

## Cannabis Indications in Oncology

Strong Evidence - green

Weak Evidence - yellow

No significant evidence - red

Chemotherapy induced nausea and vomiting

Cancer associated pain

Anorexia and cachexia syndrome

Insomnia

Depression and anxiety

Cancer treatment

Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. 2019 Mar;28(3):285-296. doi: 10.1080/13543784.2019.1561859. Epub 2018 Dec 29. PMID: 30572744.


22



23



24



There is conclusive or substantial evidence that cannabinoids are effective for the treatment of chronic pain in adults (cannabis).

National Academies of Sciences, Engineering, and Medicine 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. <https://doi.org/10.17226/24625>.

25

**Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies**

Evidence for effectiveness of cannabinoids in CNCP is limited


104 studies (9958 participants)

Those experiencing 30% reduction in pain:  
29.0% (cannabinoids) vs 25.9% (placebo)

Those experiencing 50% reduction in pain:  
18.2% (cannabinoids) vs 14.4% (placebo)

Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Munro B, Farrell M, Weier M, Degenhardt L. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. *Pain*. 2018 Oct;159(10):1932-1954. doi: 10.1093/pain/pny0000000000000000. PMID: 29867469.

26



**Medical cannabis - highest use substance for LBP in aged population (65-79) Systematic Review 23 articles**

THC binds CB1 and CB2 pain receptors  
CBD stimulates release of  $\beta$ -endorphin, suppressing pain, and CBD promotes production of body's own cannabinoids

Some studies reported **high satisfaction** for mgmt. of back pain THC/CBD  
Some studies reported **minimal relief** from chronic pain with THC/CBD

**Differences in analgesic effects** among various administration methods & ratios of THC/CBD are **currently unclear and remain a research priority.**

Senderovich H, Wagman H, Zhang D, Vinoraj D, Walrus S. The Effectiveness of Cannabis and Cannabis Derivatives in Treating Lower Back Pain in the Aged Population: A Systematic Review. *Geriatrics* 2021. doi: 10.1159/000518289

27

**Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients**

Online survey IBD patients / 838 responses  
25.3% (n = 212) respondents were current or previous users of MC

**Only 3 respondents reported using legally assessed products**

92.7% endorsed cannabis as effective in symptom mgmt: abdominal pain, stress, sleep, cramping, anxiety

Melissa J Branson, PhD, Sarah V Abalos, BSc, Susan J Connor, MD, PhD, Orsolya J Corle, MD, PhD, Lewis J Martin, PhD, Lucy K Gohil, BSc, Anastasia S Surawy, MPsychClin, Ian S McGregor, PhD. Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients. *Ordn's & Colitis* 2020. Volume 2, Issue 2, April 2020, oiaa015. <https://www.oxford.com.au/doi/10.1093/orc/obz015>

28

## Medical Cannabis Reduces Chronic or Neuropathic Pain in Advanced Cancer Patients

Review 1975-2017: 5 Clinical studies evaluating effect of THC or CBD on controlling cancer pain

THC oil capsules  
THC oromucosal spray  
THC:CBD oromucosal spray

Doses 2.7 – 42.2 mg/day THC and 0-40 mg CBD daily

Higher THC correlated in increased pain relief in most studies  
1 study found sig. pain relief in low doses

Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O'Hearn S. A selective review of medical cannabis in cancer pain management. Ann Palliat Med 2017;6(Suppl 2):S215-S222. doi: 10.21037/apm.2017.08.05

29

## Strains to relieve pain...



•**ACDC:** This is a non-psychoactive strain that makes you feel happy, uplifted, relaxed and focused. HIGH THC/HIGH CBD



•**Blackberry Kush:** High in THC, Blackberry Kush is particularly known for its intense pain-relieving effects. It also makes you feel relaxed, sleepy and euphoric and is best taken at nighttime or on days you don't have much to do



•**Harlequin:** HIGH CBD/LOW THC. Due to its CBD and THC content, Harlequin kills your pain while keeping you mentally alert. As such, this is a good option for daytime use.

<https://www.marijuanadoctors.com/conditions/cancer/>

30

## BMJ Journals

2021 Review of RCT Medical Cannabis for Pain Management  
32 trials (5174 adult patients)

Moderate to high certainty evidence shows that non-inhaled medical cannabis or cannabinoids results in a **small to very small improvement in pain relief, physical functioning, and sleep quality among patients with chronic pain**, along with several transient adverse side effects, compared with placebo.

Wong L, Hong PJ, May C, Rehman Y, et al., Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021 Sep 8;374:n1034. doi: 10.1136/bmj.n1034. PMID: 34497047.

31

## Annals of Internal Medicine®

Reviews | August 2022

### Cannabis-Based Products for Chronic Pain A Systematic Review

#### Conclusion:

Oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation. Studies are needed on long-term outcomes and further evaluation of product formulation effects.


#### Limitation:

Variation in interventions; lack of study details, including unclear availability in the United States; and inadequate evidence for some products.

Marian S. McDonagh, Benjamin J. Morasco, Jesse Wagner, et al. Cannabis-Based Products for Chronic Pain: A Systematic Review. Ann Intern Med 2022;175:1143-1153. [Epub 7 June 2022]. doi: [10.1093/annals/abn304](https://doi.org/10.1093/annals/abn304)

32






33




34



35




36



37



38



39

**Annals of Internal Medicine**

**ORIGINAL RESEARCH**

**Acute Illness Associated With Cannabis Use, by Route of Exposure**

**An Observational Study**

Monte AA, Shelton SK, et al. *Ann Intern Med*. 2016;165(11):755-762. doi:10.7326/M16-2809

**Background:** Cannabis use is associated with acute illness, but the route of exposure is unclear. We evaluated acute illness associated with cannabis use by route of exposure.

**Design:** Retrospective cohort study.

**Setting:** Emergency department.

**Participants:** Patients with acute illness associated with cannabis use.

**Measurements and Main Results:** We identified 1,000 patients with acute illness associated with cannabis use. The most common route of exposure was smoking (55%), followed by edibles (35%), and then other routes (10%). The most common acute illness was respiratory (45%), followed by psychiatric (30%), and then cardiovascular (15%).

**Conclusions:** Cannabis use is associated with acute illness, and the route of exposure is important. Smoking is the most common route of exposure, and respiratory illness is the most common acute illness.

**Keywords:** Cannabis, acute illness, route of exposure, respiratory, psychiatric, cardiovascular.

**Abbreviations:** ER, emergency room; ED, emergency department; ICD-9, International Classification of Diseases, Ninth Revision, Clinical Modification; OR, odds ratio; CI, confidence interval.

**Introduction:** Cannabis use is associated with acute illness, but the route of exposure is unclear. We evaluated acute illness associated with cannabis use by route of exposure.

**Methods:** We conducted a retrospective cohort study of patients with acute illness associated with cannabis use. We identified 1,000 patients with acute illness associated with cannabis use. The most common route of exposure was smoking (55%), followed by edibles (35%), and then other routes (10%). The most common acute illness was respiratory (45%), followed by psychiatric (30%), and then cardiovascular (15%).

**Results:** We found that patients who used cannabis by smoking had a higher rate of respiratory illness (45%) compared to patients who used cannabis by edibles (30%) or other routes (15%). Patients who used cannabis by edibles had a higher rate of psychiatric illness (30%) compared to patients who used cannabis by smoking (25%) or other routes (10%). Patients who used cannabis by other routes had a higher rate of cardiovascular illness (15%) compared to patients who used cannabis by smoking (10%) or edibles (5%).

**Conclusions:** Cannabis use is associated with acute illness, and the route of exposure is important. Smoking is the most common route of exposure, and respiratory illness is the most common acute illness.

**Limitations:** This study was limited by its retrospective design and the potential for confounding by other factors.

**Conclusion:** Cannabis use is associated with acute illness, and the route of exposure is important. Smoking is the most common route of exposure, and respiratory illness is the most common acute illness.

ER visits evaluated between January 1, 2012 and December 31, 2016.

**Edible** products accounted for **10.7%** of cannabis-attributable visits in Colorado


**Edibles** ER visits:  
Acute psychiatric symptoms: **18%**  
Intoxication **48%**  
Cardiovascular symptoms **8%**

Monte AA, Shelton SK, et al. Acute illness associated with cannabis use, by Route of exposure. *An Observational Study*. *Ann Intern Med*. doi:10.7326/M16-2809


40




41



42



43



44

Potential Applications of Secondary Metabolites of <i>C. sativa</i> L. in Dentistry	Appropriate Property of Secondary Metabolite	Reference
<b>Cannabinoids</b>		
1. General oral hygiene (Cannabidiol, delta9-tetrahydrocannabinol, ajulemic acid, Cannabigerol)	Antifungal Antibacterial	[41,84,93,105,117,118,210]
2. Toothache (Cannabidiol, HU-320)	Analgesic	[41,151,163]
3. Dental caries/cavities (Cannabidiol, Cannabigerol and Delta9-tetrahydrocannabinol)	Anti-bacterial Analgesic	[41,47,48,84,93,117,118,191,211]
4. Abscesses (Cannabidiol and delta9-tetrahydrocannabinol)	Anti-bacterial Anti-puritic	[191]
5. Prevention of biofilm attachment on teeth (Cannabidiol and delta9-tetrahydrocannabinol)	Anti-bacterial	[84,191]
6. Burning Mouth Syndrome (Cannabidiol)	Analgesic	[191]
7. Oral and Salivary Gland Cancers (Cannabidiol)	Anti-cancer Anti-metastatic	[191]

Lowe, H.; Toyang, N.; Steele, B.; Bryant, J.; Ngwa, W.; Nedamat, K. The Current and Potential Application of Medicinal Cannabis Products in Dentistry. *Dent. J.* 2021, 9, 106. <https://doi.org/10.3390/d9090106>

45

Potential Applications of secondary metabolites of <i>C. sativa</i> L. in dentistry.		
8. Periodontitis (most severe form of gum disease) (Cannabidiol, HU-320, delta9-tetrahydrocannabinol, AEA)	Anti-bacterial Anti-inflammatory Analgesic	[84,151,188,191,212,213]
9. Periodontal (Gum) disease (Cannabidiol, delta9-tetrahydrocannabinol, Cannabigerol and HU-320)	Anti-bacterial Anti-inflammatory Analgesic	[84,93,117,118,151,211]
10. Gingivitis (Cannabidiol, delta9-tetrahydrocannabinol, Cannabigerol, and HU-320)	Anti-bacterial Anti-inflammatory Analgesic	[84,93,117,118,151,211]
11. Oral Mucositis and other forms of oral cancer (Cannabidiol, delta9-tetrahydrocannabinol, JWH-133m, WIN-55,212-2, Cannabidiol, Cannabicyclol)	Anti-bacterial Anti-cancer Anti-metastatic Anti-inflammatory Analgesic Antioxidant	[84,154,191,192,198,214]
12. Dental Anxiety (Cannabidiol)	Anxiolytic	[191,215]
13. Sleep issues resulting from dental anxiety (Cannabidiol and delta-9-tetrahydrocannabinol (THC))	Relaxant	[216]

Lowe, H.; Toyang, N.; Steele, B.; Bryant, J.; Ngwa, W.; Nedamat, K. The Current and Potential Application of Medicinal Cannabis Products in Dentistry. *Dent. J.* 2021, 9, 106. <https://doi.org/10.3390/d9090106>

46



47



48



**ORAL DISEASES**  
Leading international journal of oral health

REVIEW ARTICLE  
**The effects of cannabis use on oral health**  
Chunyan Liu, Xia Qi, Dongru Yang, Anthony Neely, Zheng Zhou  
First published: 02 December 2019 | <https://doi.org/10.1111/odi.13246> | Citations: 2

Due to insufficient information, **more well-designed studies** should be conducted.

It is urgent to include cannabis usage into **dental patient health records**.

As the leading method of consuming cannabis, marijuana smoking may pose **direct and indirect effects on oral health**.

provisional evidence concerning the effects of cannabis use on oral health. Due to insufficient information, more well-designed studies should be conducted. It is urgent to include cannabis usage into dental patient health records.

49

## Oral health

In a statewide survey of California dentists and dental hygienists, only **1 in 4** reported asking patients about cannabis, in contrast to the approximately 60% who asked specifically about tobacco cigarettes.

Chaffee BW, Urata J, Cough ET, Silverstein S. Dental professionals' engagement in tobacco, electronic cigarette and cannabis patient counseling. JDR Clin Trans Res 2020Apr;5(2):133-145. doi: 10.1177/2380084419861384. Epub 2019 Jul 19.

50

## Medical History

Are you currently using any form of Cannabis for medical or recreational purposes?

Chaffee BW, Urata J, Cough ET, Silverstein S. Dental professionals' engagement in tobacco, electronic cigarette and cannabis patient counseling. JDR Clin Trans Res 2020Apr;5(2):133-145. doi: 10.1177/2380084419861384. Epub 2019 Jul 19.

51


## Cannabis: A joint problem for patients and the dental profession

Table 2 The difference between tobacco and cannabis
Cannabis joints are usually smoked for a <u>longer period of time</u> than tobacco. <sup>4</sup>
Cannabis joints are usually <u>smoked to a shorter joint length</u> , which results in a greater number of toxins entering the mouth. <sup>4</sup>
Cannabis has a <u>higher combustion temperature</u> compared to tobacco. <sup>4</sup>
There is greater carboxyhaemoglobin <u>concentration and tar retention in lower airway</u> in cannabis smokers. <sup>4</sup>
Tobacco found in cigarettes is regulated. Whereas, cannabis is a <u>non-regulated substance</u> .

Joshi, S., Ashley, M. Cannabis: A joint problem for patients and the dental profession. Br Dent J 220, 597-601 (2016). <https://doi.org/10.1038/s41641-016-0116-4>. \*Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: Consideration of the literature. Respirology 2014; 3: 655-662.

52

## Cannabis: A joint problem for patients and the dental profession




22-year-old patient who smoked six cannabis 'joints' a day for the last 8 years.  
Cannabis users surveyed: 63% who experienced increased hunger post use – favored sweets  
Various studies show 2.5 – 6 times higher decay rates in cannabis users compare to non-users

Joshi, S., Ashley, M. Cannabis: A joint problem for patients and the dental profession. *Br Dent J* 220, 597–601 (2016).  
<https://doi.org/10.1038/sj.bdj.2016.416>

53

## Cannabis: A joint problem for patients and the dental profession



Darling *et al.*,<sup>19</sup> dry mouth was experienced by 69.6% of its participants after smoking cannabis  
Increased risk of Candida infections

Joshi, S., Ashley, M. Cannabis: A joint problem for patients and the dental profession. *Br Dent J* 220, 597–601 (2016).  
<https://doi.org/10.1038/sj.bdj.2016.416>

54

## Cannabis: A joint problem for patients and the dental profession

A sample size of 85 participants were used and divided into two groups. The control group were tobacco smokers only and the test group used cannabis and tobacco

The results obtained showed that cannabis users brushed their teeth less frequently than the control group. In addition, the control group visited their dentist more regularly whereas only 21% in the test group visited their dentist annually.

Joshi, S., Ashley, M. Cannabis: A joint problem for patients and the dental profession. *Br Dent J* 220, 597–601 (2016).  
<https://doi.org/10.1038/sj.bdj.2016.416>

55

**HHS Public Access**  
Author manuscript  
J Calif Dent Assoc. Author manuscript; available in PMC 2021 September 03.  
Published in final edited form as:  
J Calif Dent Assoc. 2021 August; 49(8): 493-501.

**Cannabis Use and Oral Health in a National Cohort of Adults**  
Benjamin W. Chaffee, DDS, MPH, PhD  
Associate professor of oral epidemiology and dental public health  
San Francisco, School of Dentistry

**Abstract**  
**Background:** Cannabis use is increasing and increasing among adolescents, yet few prospective studies have examined associations between cannabis use and oral health outcomes. **Methods:** This investigation examined associations between cannabis use and oral health outcomes among participants (N = 18,872) in Tobacco and Health (PATH) Study, a nationally representative cohort including estimated associations between cannabis use and seven health outcomes, adjusted for tobacco use and other dental risk factors. **Results:** Reporting past 30-day cannabis use in any PATH Waves 1-7 was positively and statistically significantly associated at Wave 4 with multiple periodontal outcomes, including periodontitis (OR 1.32, 95% CI 1.02-1.71). **Conclusions:** These findings provide further evidence that cannabis use is associated with poor oral health, although study limitations and implications for clinical practice must be considered. **Practical implications:** Dental professionals should engage patients in non-judgmental dialog about cannabis use to address oral health risks and avoid potential patient safety issues in care delivery. Clinical recommendations for addressing cannabis use in dental practice are provided.

18, 872 users – self reported outcomes

Cannabis is an independent risk factor for poor oral health, although study limitations (limited information on cannabis use frequency and modality must be considered)

Dental professionals should engage patients in non-judgmental dialog about cannabis use

Chaffee BW. Cannabis Use and Oral Health in a National Cohort of Adults. *J Calif Dent Assoc.* 2021;49(8):493-501.

56




57



58



59



60



61



62